Engineered Stem Cells Modulate Bioelectric Properties for Cardiac Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem-cell therapies for heart failure show modest and inconsistent improvements in cardiac function, necessitating enhanced methods to improve the reparative potential of transplanted cells.
Innovation Solution
Modulating the bioelectric properties of stem cells by increasing the expression of the intermediate-conductance Ca2+-activated K+ channel (KCa3.1) to hyperpolarize the transmembrane potential, thereby enhancing proliferation, differentiation, and cytokine secretion, using cardiac explant-derived stem cells (EDCs) for improved cardiac function through angiogenesis and cardiomyogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cell therapy is used to treat heart failure, then cardiac function improvement is achieved, but the improvement is modest and inconsistent
Solution Approach 1:
The patent modulates the bioelectric properties of stem cells by altering ion channel expression levels, specifically increasing intermediate-conductance Ca2+-activated K+ channels to hyperpolarize transmembrane potential. This parameter change in cellular electrophysiology transforms the stem cells into a more effective therapeutic agent, resolving the inconsistency and modesty of cardiac function improvement by standardizing and enhancing the cellular response.
Solution Approach 2:
The patent applies ex vivo preconditioning to stem cells before transplantation, where the cells are genetically modified to overexpress specific ion channels in advance. This preliminary modification of cellular bioelectric properties ensures that the transplanted cells are pre-optimized for therapeutic effectiveness, thereby improving consistency and magnitude of cardiac function recovery.
2Reliability
If ion channel expression is increased to hyperpolarize transmembrane potential, then cellular reparative potential is enhanced, but cellular complexity increases
Solution Approach 1:
The patent uses viral vectors as intermediary carriers to deliver genetic material into stem cells. This intermediary approach simplifies the genetic modification process compared to direct gene editing methods, as viral vectors are well-established tools that efficiently transduce target cells with desired genetic sequences, thereby enhancing reparative potential while managing complexity through proven delivery mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The increased expression of KCa3.1 channels in EDCs leads to enhanced cardiac function, increased angiogenesis, cardiomyocyte proliferation, and reduced myocardial scar burden without increasing malignant cardiac rhythms, improving cardiac function and cell engraftment.
Implementation Method 1
the modulated bioelectric property is ahyperpolarized transmembrane potential. In a further embodiment, thehyperpolarized transmembrane potential is a result of an increased expression of theintermediate-conductance Ca2+-activated K+ channel
Data Source
AI summary
There is disclosed a cardiac explant-derived stem cell (EDC), the cell comprising a gene encoding an intermediate-conductance Ca2+-activated K+ channel, and wherein the gene causes an overexpression of the intermediate-conductance Ca2+-activated K+ channel, and methods of producing same. There is also disclosed a method of producing engineered EDCs having a modulated bioelectric property, the method comprising: obtaining EDCs; introducing a KCNN4 gene into the EDCs to increase the expression of KCa3.1 channels, to produce engineered EDCs. There is also disclosed a composition for treating or ameliorating a damaged myocardium in a subject, the composition comprising extracellular vesicles isolated from cultures of engineered EDCs. There is also disclosed a method for treating or ameliorating a damaged myocardium in a subject, comprising administering the engineered EDCs or the extracellular vesicles isolated from cultures of engineered EDCs to the damaged myocardium of the subject.